Cadila granted US FDA approval to market antidepressant
Essential IR Insights Newsletter Fall - 2023
A Corporation Clearly Pinpoints Activist Investor Activity
Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise
Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises
The U.S. Food and Drug Administration granted Cadila Healthcare Ltd. approval to market a generic version of an antidepressant drug.
The Indian pharmaceutical company will market mirtazapine in three doses, which will be produced at its manufacturing facility in Baddi, India.
